American Express Reveals 2023 Top Travel Trends
23.3.2023 16:00:00 EET | Business Wire | Press release
American Express Travel® released their 2023 Global Travel Trends Report today, highlighting four global trends inspiring people to travel this year:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005091/en/
American Express Travel's 2023 Global Travel Trends Report
- The Rise of “Set-Jetting”: Popular movies, TV shows and social media are inspiring people to travel to places they see onscreen, like Italy, Paris, Yellowstone, and London
- Delicious Destinations: From top restaurants to local favorites to cooking classes, people are choosing their next destination based on what they’ll eat
- A Wellness Wave: Restorative vacations are on the rise as travelers prioritize self-care and mental and physical health
- Traveling Off the Beaten Path: Travelers want to discover hidden gems and support the local community when they visit
The report, based on survey data from travelers from the United States, Australia, Canada, Mexico, Japan, India and the United Kingdom, found that more than half (52%) of respondents say they plan to take more trips this year than last year and 50% of respondents are planning to spend more money on travel in 2023 than 2022. 84% of Gen Z and Millennials surveyed would rather take a dream vacation than purchase a new luxury item, and 79% agree that travel is an important budget priority.
“Vacations are precious, and travelers are prioritizing personalized itineraries built around their passions, from planning an entire vacation for a single dinner reservation to getting the perfect video for TikTok,” says Audrey Hendley, President of American Express Travel. “No matter what the inspiration is, American Express Travel Consultants have the expertise to help every type of traveler plan all types of trips.”
Top insights from American Express Travel’s 2023 Global Travel Trends Report include:
-
Pop culture and social media are influencing the rise of “set-jetting,” especially among younger travelers.
- 75% of respondents agree that they have been inspired to travel to a specific destination by social media
- 70% of Gen Z and Millennials surveyed agree that they have been inspired to visit a destination after seeing it featured in a TV show, news source, or movie
-
46% of Gen Z and Millennials surveyed say they have been inspired to travel to a destination because of Instagram
-
From visiting top restaurants and local favorites to taking a cooking class, food has a huge impact on where people travel.
- 81% of respondents agree that trying local foods and cuisines is the part of traveling they look forward to the most
- 66% of Gen Z and Millennials surveyed agree that they get most of their eating-while-traveling inspiration from social media
-
Nearly half (47%) of Gen Z and Millennials surveyed agree that they have planned an entire trip around visiting a specific restaurant
-
Prioritizing self-care is leading to a rise in restorative vacations.
- 73% of respondents are planning vacations to better their mental, physical, and emotional health this year
-
60% of Gen Z and Millennials surveyed say they go out of their way to book hotels that offer spa and wellness services
-
Travelers want to discover hidden gems and support the local communities they visit.
- 85% of respondents want to visit a place where they can truly experience the local culture
- 78% of respondents are interested in going on vacations that support local communities in 2023
As the demand for travel continues into 2023, American Express Travel provides eligible Card Members with exceptional travel access, including 1,400+ airport lounges through its Global Lounge Collection; 7,000+ Travel Consultants; restaurant reservations through Resy and curated where-to-eat guides at Resy.com/Travel; benefits at 2,000+ hand-picked hotels around the world via Fine Hotels + Resorts® and The Hotel Collection; and more.
The full American Express Travel 2023 Global Travel Trends Report can be viewed here.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress, instagram.com/americanexpress, linkedin.com/company/american-express, twitter.com/americanexpress, and youtube.com/americanexpress.
Key links to products, services and corporate responsibility information: personal cards, business cards and services, travel services, gift cards, prepaid cards, merchant services, Accertify, Kabbage , Resy, corporate card, business travel, diversity and inclusion, corporate responsibility and Environmental, Social, and Governance reports.
Methodology:
1The American Express 2023 Global Travel Trends Report is based on data obtained through an online poll conducted by Morning Consult between February 3rd – 11th, 2023 among a sample of 1,000 travelers from Australia, Canada, India, Japan, Mexico, UK and 2,000 travelers in the US who have a household income of at least a $70k equivalent, and who typically travel by air at least once a year. Results from each market’s survey have a margin of error of plus or minus 3 percentage points.
2Gen Z and Millennials are defined as respondents as being born between 1981 - 2012.
Seller of Travel
American Express Travel Related Services Company, Inc. is acting solely as a sales agent for travel suppliers and is not responsible for the actions or inactions of such suppliers. Certain suppliers pay us commission and other incentives for reaching sales targets or other goals and may provide incentives to our Travel Consultants. For more information visit www.americanexpress.com/travelterms.
California CST#1022318; Washington UBI#600-469-694
Source: American Express Company
Location: New York
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005091/en/
Contact information
AMERICAN EXPRESS
Emily Vicker
Emily.Vicker@aexp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom